home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 04/28/20

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - VistaGen up 7% on foray into COVID-19

Thinly traded nano cap VistaGen Therapeutics ( OTC:VTGN +7.3% ) is up in early trade on double normal volume in reaction to its plan to expand development of PH94B, a rapid-onset neuroactive nasal spray, to include the potential treatment of adjustment disorder related to the stress of t...
VTGN - VistaGen +26% premarket on expanded use of PH94B

VistaGen Therapeutics ( OTC:VTGN ) plans to expand clinical development of PH94B, its rapid-onset neuroactive nasal spray, to include treatment of adjustment disorder due to stressors related to the COVID-19 pandemic. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, Sto...

VTGN - VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19

SOUTH SAN FRANCISCO, Calif. , April 28, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with high unmet medical...

VTGN - VistaGen Therapeutics inks $10M stock purchase agreement; shares up 13% premarket

VistaGen Therapeutics ( OTC:VTGN ) announces a common stock purchase agreement with Lincoln Park Capital Fund, for up to $10.25M. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

VTGN - VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million

SOUTH SAN FRANCISCO, Calif. , March 25, 2020 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and central nervous system (CNS) diseases and disorders with high unmet medical ...

VTGN - VistaGen up 15% premarket on positive PH10 data

Nano cap VistaGen Therapeutics (NASDAQ: VTGN ) jumps  15%  premarket on increased volume in response to positive results from a single-site, 30-subject Phase 2a clinical trial evaluating PH10, a rapid-onset synthetic neurosteroid nasal spray, in patients with major depressive dis...

VTGN - VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder

SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2020 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced pos...
VTGN - Relmada Therapeutics: A Promising Depression Focused Player For 2020

Today, we will study why Relmada Therapeutics (RLMD) is an attractive clinical-stage biopharmaceutical pick in 2020. Company overview Relmada Therapeutics is a clinical-stage biotechnology company focused on advancing REL-1017 (d-methadone or dextromethadone) as a rapid-acting oral treat...

VTGN - VistaGen Therapeutics reports Q3 results

VistaGen Therapeutics ( OTC:VTGN ): Q3 GAAP EPS of -$0.15. More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

VTGN - VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview

SOUTH SAN FRANCISCO, Calif. , Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced financia...
Previous 10 Next 10